--- title: "Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/286962960.md" description: "Inventiva (ENXTPA:IVA) is currently trading at €4.25, facing recent volatility with a 3.41% drop in one day and a 13.44% decline over the past week. Despite this, it has a 1-year total shareholder return of 49.12%. Analysts project a fair value of €10.00, indicating it may be undervalued. However, concerns remain about potential underperformance in clinical trials and ongoing losses. Investors are encouraged to assess risks and rewards before making decisions." datetime: "2026-05-19T20:27:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286962960.md) - [en](https://longbridge.com/en/news/286962960.md) - [zh-HK](https://longbridge.com/zh-HK/news/286962960.md) --- # Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility Inventiva (ENXTPA:IVA) has drawn investor attention after recent trading saw the stock at €4.25, with moves over the past month and past 3 months prompting closer scrutiny of its clinical-stage pipeline and financial profile. See our latest analysis for Inventiva. Recent trading has been choppy, with the 1 day share price return down 3.41% and the 7 day share price return down 13.44%. However, the 1 year total shareholder return of 49.12% and 3 year total shareholder return of 48.08% show that longer term holders have still seen sizeable gains. If you are weighing Inventiva against other potential ideas in healthcare, it can be useful to see what else is on the move through our screener of 121 healthcare AI stocks With Inventiva trading at €4.25 against an analyst price target near €9.97 and still reporting losses, you need to decide: is this an undervalued MASH specialist, or is the market already pricing in its future potential? ## Most Popular Narrative: 58% Undervalued With Inventiva last closing at €4.25 against a narrative fair value of about €10.00, the most followed valuation story sees a large gap between price and projected potential. > _Analysts are assuming Inventiva's revenue will grow by 194.0% annually over the next 3 years._ > > _Analysts are not forecasting that Inventiva will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Inventiva's profit margin will increase from 5238.0% below breakeven to the average GB Biotechs industry of 39.6% in 3 years._ Read the complete narrative. Want to see what kind of revenue ramp and margin reset need to line up for that fair value? The narrative leans on steep growth, richer margins, and a punchy future earnings multiple. The exact mix of assumptions might surprise you. **Result: Fair Value of €10.00 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if lanifibranor underperforms in Phase 3, or if ongoing losses and funding needs lead to heavier dilution than analysts expect. Find out about the key risks to this Inventiva narrative. ## Next Steps With that mix of optimism and concern in mind, take a moment to review the numbers yourself and decide where you stand on the balance of risks and rewards, starting with 1 key reward and 4 important warning signs ## Looking for more investment ideas? If Inventiva has you thinking about where to go next, do not stop here. The right stock shortlist can be the difference between reacting late and acting early. - Target potential mispricings by scanning 229 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile. - Prioritise resilience by reviewing 307 resilient stocks with low risk scores that score well on stability so short term swings are less likely to derail your long term plan. - Hunt for fresh opportunities by checking the screener containing 540 high quality undiscovered gems that many investors may not be watching yet, before the wider market catches on. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [IVA.US](https://longbridge.com/en/quote/IVA.US.md) ## Related News & Research - [Do Wall Street Analysts Like PTC Inc. Stock?](https://longbridge.com/en/news/286906040.md) - [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md) - [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md) - [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md) - [Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs](https://longbridge.com/en/news/287197958.md)